395 related articles for article (PubMed ID: 35091289)
1. Design, synthesis, in vitro antiproliferative evaluation and in silico studies of new VEGFR-2 inhibitors based on 4-piperazinylquinolin-2(1H)-one scaffold.
Hassan A; Badr M; Abdelhamid D; Hassan HA; Abourehab MAS; Abuo-Rahma GEA
Bioorg Chem; 2022 Mar; 120():105631. PubMed ID: 35091289
[TBL] [Abstract][Full Text] [Related]
2. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
[TBL] [Abstract][Full Text] [Related]
3. Molecular Docking and In Vitro Anticancer Screening of Synthesized Arylthiazole linked 2H-indol-2-one Derivatives as VEGFR-2 Kinase Inhibitors.
Shalmali N; Bawa S; Ali MR; Kalra S; Kumar R; Zeya B; Rizvi MA; Partap S; Husain A
Anticancer Agents Med Chem; 2022; 22(11):2166-2180. PubMed ID: 34792005
[TBL] [Abstract][Full Text] [Related]
4. Novel 4-(piperazin-1-yl)quinolin-2(1H)-one bearing thiazoles with antiproliferative activity through VEGFR-2-TK inhibition.
Hassan A; Badr M; Hassan HA; Abdelhamid D; Abuo-Rahma GEA
Bioorg Med Chem; 2021 Jun; 40():116168. PubMed ID: 33962153
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors.
Abdullaziz MA; Abdel-Mohsen HT; El Kerdawy AM; Ragab FAF; Ali MM; Abu-Bakr SM; Girgis AS; El Diwani HI
Eur J Med Chem; 2017 Aug; 136():315-329. PubMed ID: 28505536
[TBL] [Abstract][Full Text] [Related]
6. Design, green synthesis, molecular docking and anticancer evaluations of diazepam bearing sulfonamide moieties as VEGFR-2 inhibitors.
Saleh NM; El-Gaby MSA; El-Adl K; Abd El-Sattar NEA
Bioorg Chem; 2020 Nov; 104():104350. PubMed ID: 33142416
[TBL] [Abstract][Full Text] [Related]
7. Novel 1,3-Thiazole Analogues with Potent Activity against Breast Cancer: A Design, Synthesis, In Vitro, and In Silico Study.
Salem MG; El-Maaty DMA; El-Deen YIM; Elesawy BH; Askary AE; Saleh A; Saied EM; Behery ME
Molecules; 2022 Jul; 27(15):. PubMed ID: 35956848
[TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of new 2-oxoquinoxalinyl-1,2,4-triazoles as antitumor VEGFR-2 inhibitors.
Zengin M; Unsal Tan O; Arafa RK; Balkan A
Bioorg Chem; 2022 Apr; 121():105696. PubMed ID: 35217379
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and molecular docking of new [1,2,4] triazolo[4,3-a]quinoxaline derivatives as anticancer agents targeting VEGFR-2 kinase.
Alsaif NA; Elwan A; Alanazi MM; Obaidullah AJ; Alanazi WA; Alasmari AF; Albassam H; Mahdy HA; Taghour MS
Mol Divers; 2022 Aug; 26(4):1915-1932. PubMed ID: 34460053
[TBL] [Abstract][Full Text] [Related]
10. VEGFR-2 inhibiting effect and molecular modeling of newly synthesized coumarin derivatives as anti-breast cancer agents.
Ahmed EY; Abdel Latif NA; El-Mansy MF; Elserwy WS; Abdelhafez OM
Bioorg Med Chem; 2020 Mar; 28(5):115328. PubMed ID: 31992477
[TBL] [Abstract][Full Text] [Related]
11. Novel potent substituted 4-amino-2-thiopyrimidines as dual VEGFR-2 and BRAF kinase inhibitors.
Abdel-Mohsen HT; Omar MA; El Kerdawy AM; Mahmoud AEE; Ali MM; El Diwani HI
Eur J Med Chem; 2019 Oct; 179():707-722. PubMed ID: 31284081
[TBL] [Abstract][Full Text] [Related]
12. Design and biological evaluation of 3-substituted quinazoline-2,4(1
Hassan A; Mubarak FAF; Shehadi IA; Mosallam AM; Temairk H; Badr M; Abdelmonsef AH
J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2189578. PubMed ID: 36919632
[TBL] [Abstract][Full Text] [Related]
13. Discovery of new quinoxaline-2(1H)-one-based anticancer agents targeting VEGFR-2 as inhibitors: Design, synthesis, and anti-proliferative evaluation.
El-Adl K; Sakr HM; Yousef RG; Mehany ABM; Metwaly AM; Elhendawy MA; Radwan MM; ElSohly MA; Abulkhair HS; Eissa IH
Bioorg Chem; 2021 Sep; 114():105105. PubMed ID: 34175720
[TBL] [Abstract][Full Text] [Related]
14. New proapoptotic chemotherapeutic agents based on the quinolone-3-carboxamide scaffold acting by VEGFR-2 inhibition.
El-Fakharany ZS; Nissan YM; Sedky NK; Arafa RK; Abou-Seri SM
Sci Rep; 2023 Jul; 13(1):11346. PubMed ID: 37443185
[TBL] [Abstract][Full Text] [Related]
15. N-Substituted-4-phenylphthalazin-1-amine-derived VEGFR-2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluation studies.
El-Adl K; Ibrahim MK; Khedr F; Abulkhair HS; Eissa IH
Arch Pharm (Weinheim); 2021 Mar; 354(3):e2000219. PubMed ID: 33197080
[TBL] [Abstract][Full Text] [Related]
16. Design and synthesis of new 1,6-dihydropyrimidin-2-thio derivatives targeting VEGFR-2: Molecular docking and antiproliferative evaluation.
Marzouk AA; Abdel-Aziz SA; Abdelrahman KS; Wanas AS; Gouda AM; Youssif BGM; Abdel-Aziz M
Bioorg Chem; 2020 Sep; 102():104090. PubMed ID: 32683176
[TBL] [Abstract][Full Text] [Related]
17. Novel VEGFR-2 inhibitors as antiangiogenic and apoptotic agents via paracrine and autocrine cascades: Design, synthesis, and biological evaluation.
Abdel Rahman DE; Fouad MA; Mohammed ER; El-Zoheiry HH; Abdelrasheed Allam H
Bioorg Chem; 2023 Oct; 139():106678. PubMed ID: 37354661
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, molecular docking, and anticancer evaluations of 1-benzylquinazoline-2,4(1H,3H)-dione bearing different moieties as VEGFR-2 inhibitors.
El-Adl K; El-Helby AA; Sakr H; El-Hddad SSA
Arch Pharm (Weinheim); 2020 Aug; 353(8):e2000068. PubMed ID: 32510731
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, biological evaluation, and modeling studies of novel conformationally-restricted analogues of sorafenib as selective kinase-inhibitory antiproliferative agents against hepatocellular carcinoma cells.
Sbenati RM; Zaraei SO; El-Gamal MI; Anbar HS; Tarazi H; Zoghbor MM; Mohamood NA; Khakpour MM; Zaher DM; Omar HA; Alach NN; Shehata MK; El-Gamal R
Eur J Med Chem; 2021 Jan; 210():113081. PubMed ID: 33310290
[TBL] [Abstract][Full Text] [Related]
20. Novel 3-phenylquinazolin-2,4(1H,3H)-diones as dual VEGFR-2/c-Met-TK inhibitors: design, synthesis, and biological evaluation.
Hassan A; Mosallam AM; Ibrahim AOA; Badr M; Abdelmonsef AH
Sci Rep; 2023 Oct; 13(1):18567. PubMed ID: 37903949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
